Clinical Trial

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2026 (before its estimated May 29, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-29; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2025-09-08
Trial Details
NCT Number NCT07160400
Lead Sponsor Innovent Biologics Technology Limited (Shanghai R&D Center)
Conditions Part A: Healthy Part B: Overweight or Obesity
Enrollment 104 participants
Start Date 2025-09-04
Primary Completion 2026-05-29 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-08